These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 21420419)

  • 1. Modelling the impact of acute infection dynamics on the accumulation of HIV-1 mutations.
    Shiri T; Welte A
    J Theor Biol; 2011 Jun; 279(1):44-54. PubMed ID: 21420419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
    Martinez-Picado J; Martínez MA
    Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of delays in cell infection and virus production on HIV-1 dynamics.
    Zhu H; Zou X
    Math Med Biol; 2008 Jun; 25(2):99-112. PubMed ID: 18504248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug induced superinfection in HIV and the evolution of drug resistance.
    Leontiev VV; Maury WJ; Hadany L
    Infect Genet Evol; 2008 Jan; 8(1):40-50. PubMed ID: 18024234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mathematical model of HIV infection: Simulating T4, T8, macrophages, antibody, and virus via specific anti-HIV response in the presence of adaptation and tropism.
    Wasserstein-Robbins F
    Bull Math Biol; 2010 Jul; 72(5):1208-53. PubMed ID: 20151219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A stochastic model for early HIV-1 population dynamics.
    Tuckwell HC; Le Corfec E
    J Theor Biol; 1998 Dec; 195(4):451-63. PubMed ID: 9837702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On modeling the effects of T-cell vaccines on HIV acquisition and disease.
    Wick WD
    Stat Med; 2008 Oct; 27(23):4805-16. PubMed ID: 18265425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-host evolution of human immunodeficiency virus type 1 and viral fitness.
    Clementi M; Canducci F; Bagnarelli P; Menzo S
    New Microbiol; 2004 Apr; 27(2 Suppl 1):41-4. PubMed ID: 15646063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of imperfect vaccines on the evolution of HIV virulence.
    Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
    Med Hypotheses; 2006; 66(5):907-11. PubMed ID: 16442745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients.
    Charpentier C; Nora T; Tenaillon O; Clavel F; Hance AJ
    J Virol; 2006 Mar; 80(5):2472-82. PubMed ID: 16474154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral and host factors in the pathogenesis of HIV infection.
    Derdeyn CA; Silvestri G
    Curr Opin Immunol; 2005 Aug; 17(4):366-73. PubMed ID: 15955686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 15. Mechanism of HIV persistence: implications for vaccines and therapy.
    Bremermann HJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Aug; 9(5):459-83. PubMed ID: 7627623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hitting HIV where it hurts: an alternative approach to HIV vaccine design.
    Altfeld M; Allen TM
    Trends Immunol; 2006 Nov; 27(11):504-10. PubMed ID: 16997629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population.
    Pillay D
    Antivir Ther; 2001; 6 Suppl 3():15-24. PubMed ID: 11678470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of HIV immune escape and reversion: implications for vaccination.
    Davenport MP; Loh L; Petravic J; Kent SJ
    Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.
    Burke B; Derby NR; Kraft Z; Saunders CJ; Dai C; Llewellyn N; Zharkikh I; Vojtech L; Zhu T; Srivastava IK; Barnett SW; Stamatatos L
    Virology; 2006 Nov; 355(2):138-51. PubMed ID: 16920175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of an Italian multicentric care network for early HIV infection diagnosis: 1999-2001 report.
    Capiluppi B; Saracco A; Gianotti N; Mussini C; Butini L; Tomasoni L; De Gennaro M; Rizzolo L; Monolo G; Cargnel A; Moioli C; Arici C; Portelli V; Rizzardini G; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):73-8. PubMed ID: 12003179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.